Cargando…

Lipid hydroperoxides and oxylipins are mediators of denervation induced muscle atrophy

Loss of innervation is a key driver of age associated muscle atrophy and weakness (sarcopenia). Our laboratory has previously shown that denervation induced atrophy is associated with the generation of mitochondrial hydroperoxides and lipid mediators produced downstream of cPLA(2) and 12/15 lipoxyge...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Jacob L., Peelor, Fredrick F., Georgescu, Constantin, Wren, Jonathan D., Kinter, Michael, Tyrrell, Victoria J., O'Donnell, Valerie B., Miller, Benjamin F., Van Remmen, Holly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593840/
https://www.ncbi.nlm.nih.gov/pubmed/36283174
http://dx.doi.org/10.1016/j.redox.2022.102518
_version_ 1784815262441144320
author Brown, Jacob L.
Peelor, Fredrick F.
Georgescu, Constantin
Wren, Jonathan D.
Kinter, Michael
Tyrrell, Victoria J.
O'Donnell, Valerie B.
Miller, Benjamin F.
Van Remmen, Holly
author_facet Brown, Jacob L.
Peelor, Fredrick F.
Georgescu, Constantin
Wren, Jonathan D.
Kinter, Michael
Tyrrell, Victoria J.
O'Donnell, Valerie B.
Miller, Benjamin F.
Van Remmen, Holly
author_sort Brown, Jacob L.
collection PubMed
description Loss of innervation is a key driver of age associated muscle atrophy and weakness (sarcopenia). Our laboratory has previously shown that denervation induced atrophy is associated with the generation of mitochondrial hydroperoxides and lipid mediators produced downstream of cPLA(2) and 12/15 lipoxygenase (12/15-LOX). To define the pathological impact of lipid hydroperoxides generated in denervation-induced atrophy in vivo, we treated mice with liproxstatin-1, a lipid hydroperoxide scavenger. We treated adult male mice with 5 mg/kg liproxstain-1 or vehicle one day prior to sciatic nerve transection and daily for 7 days post-denervation before tissue analysis. Liproxstatin-1 treatment protected gastrocnemius mass and fiber cross sectional area (∼40% less atrophy post-denervation in treated versus untreated mice). Mitochondrial hydroperoxide generation was reduced 80% in vitro and by over 65% in vivo by liproxstatin-1 treatment in denervated permeabilized muscle fibers and decreased the content of 4-HNE by ∼25% post-denervation. Lipidomic analysis revealed detectable levels of 25 oxylipins in denervated gastrocnemius muscle and significantly increased levels for eight oxylipins that are generated by metabolism of fatty acids through 12/15-LOX. Liproxstatin-1 treatment reduced the level of three of the eight denervation-induced oxylipins, specifically 15-HEPE, 13-HOTrE and 17-HDOHE. Denervation elevated protein degradation rates in muscle and treatment with liproxstatin-1 reduced rates of protein breakdown in denervated muscle. In contrast, protein synthesis rates were unchanged by denervation. Targeted proteomics revealed a number of proteins with altered expression after denervation but no effect of liproxstain-1. Transcriptomic analysis revealed 203 differentially expressed genes in denervated muscle from vehicle or liproxstatin-1 treated mice, including ER stress, nitric oxide signaling, Gαi signaling, glucocorticoid receptor signaling, and other pathways. Overall, these data suggest lipid hydroperoxides and oxylipins are key drivers of increased protein breakdown and muscle loss associated with denervation induced atrophy and a potential target for sarcopenia intervention.
format Online
Article
Text
id pubmed-9593840
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95938402022-10-26 Lipid hydroperoxides and oxylipins are mediators of denervation induced muscle atrophy Brown, Jacob L. Peelor, Fredrick F. Georgescu, Constantin Wren, Jonathan D. Kinter, Michael Tyrrell, Victoria J. O'Donnell, Valerie B. Miller, Benjamin F. Van Remmen, Holly Redox Biol Research Paper Loss of innervation is a key driver of age associated muscle atrophy and weakness (sarcopenia). Our laboratory has previously shown that denervation induced atrophy is associated with the generation of mitochondrial hydroperoxides and lipid mediators produced downstream of cPLA(2) and 12/15 lipoxygenase (12/15-LOX). To define the pathological impact of lipid hydroperoxides generated in denervation-induced atrophy in vivo, we treated mice with liproxstatin-1, a lipid hydroperoxide scavenger. We treated adult male mice with 5 mg/kg liproxstain-1 or vehicle one day prior to sciatic nerve transection and daily for 7 days post-denervation before tissue analysis. Liproxstatin-1 treatment protected gastrocnemius mass and fiber cross sectional area (∼40% less atrophy post-denervation in treated versus untreated mice). Mitochondrial hydroperoxide generation was reduced 80% in vitro and by over 65% in vivo by liproxstatin-1 treatment in denervated permeabilized muscle fibers and decreased the content of 4-HNE by ∼25% post-denervation. Lipidomic analysis revealed detectable levels of 25 oxylipins in denervated gastrocnemius muscle and significantly increased levels for eight oxylipins that are generated by metabolism of fatty acids through 12/15-LOX. Liproxstatin-1 treatment reduced the level of three of the eight denervation-induced oxylipins, specifically 15-HEPE, 13-HOTrE and 17-HDOHE. Denervation elevated protein degradation rates in muscle and treatment with liproxstatin-1 reduced rates of protein breakdown in denervated muscle. In contrast, protein synthesis rates were unchanged by denervation. Targeted proteomics revealed a number of proteins with altered expression after denervation but no effect of liproxstain-1. Transcriptomic analysis revealed 203 differentially expressed genes in denervated muscle from vehicle or liproxstatin-1 treated mice, including ER stress, nitric oxide signaling, Gαi signaling, glucocorticoid receptor signaling, and other pathways. Overall, these data suggest lipid hydroperoxides and oxylipins are key drivers of increased protein breakdown and muscle loss associated with denervation induced atrophy and a potential target for sarcopenia intervention. Elsevier 2022-10-20 /pmc/articles/PMC9593840/ /pubmed/36283174 http://dx.doi.org/10.1016/j.redox.2022.102518 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Brown, Jacob L.
Peelor, Fredrick F.
Georgescu, Constantin
Wren, Jonathan D.
Kinter, Michael
Tyrrell, Victoria J.
O'Donnell, Valerie B.
Miller, Benjamin F.
Van Remmen, Holly
Lipid hydroperoxides and oxylipins are mediators of denervation induced muscle atrophy
title Lipid hydroperoxides and oxylipins are mediators of denervation induced muscle atrophy
title_full Lipid hydroperoxides and oxylipins are mediators of denervation induced muscle atrophy
title_fullStr Lipid hydroperoxides and oxylipins are mediators of denervation induced muscle atrophy
title_full_unstemmed Lipid hydroperoxides and oxylipins are mediators of denervation induced muscle atrophy
title_short Lipid hydroperoxides and oxylipins are mediators of denervation induced muscle atrophy
title_sort lipid hydroperoxides and oxylipins are mediators of denervation induced muscle atrophy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593840/
https://www.ncbi.nlm.nih.gov/pubmed/36283174
http://dx.doi.org/10.1016/j.redox.2022.102518
work_keys_str_mv AT brownjacobl lipidhydroperoxidesandoxylipinsaremediatorsofdenervationinducedmuscleatrophy
AT peelorfredrickf lipidhydroperoxidesandoxylipinsaremediatorsofdenervationinducedmuscleatrophy
AT georgescuconstantin lipidhydroperoxidesandoxylipinsaremediatorsofdenervationinducedmuscleatrophy
AT wrenjonathand lipidhydroperoxidesandoxylipinsaremediatorsofdenervationinducedmuscleatrophy
AT kintermichael lipidhydroperoxidesandoxylipinsaremediatorsofdenervationinducedmuscleatrophy
AT tyrrellvictoriaj lipidhydroperoxidesandoxylipinsaremediatorsofdenervationinducedmuscleatrophy
AT odonnellvalerieb lipidhydroperoxidesandoxylipinsaremediatorsofdenervationinducedmuscleatrophy
AT millerbenjaminf lipidhydroperoxidesandoxylipinsaremediatorsofdenervationinducedmuscleatrophy
AT vanremmenholly lipidhydroperoxidesandoxylipinsaremediatorsofdenervationinducedmuscleatrophy